Lastly, a challenge in the field stemming from the clinically silent nature of PanINs and PanIN progression is the absence of a surrogate marker for pre-malignant progression
A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes
The STEP clinical trial program demonstrated that semaglutide consistently produced 10.9% to 14.9% weight loss across diverse patient populations, with 83.5% of participants achieving clinically meaningful weight loss of 5% or more
The country's expanding private healthcare sector demonstrates willingness to adopt new obesity pharmacotherapy despite high treatment costs
Cancer Epidemiol
"Stimulation of cloned human glucagon-like peptide 1 receptor expressed in HEK 293 cells induces cAMP-dependent activation of calcium-induced calcium release"
